Cargando…

Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer

BACKGROUND: Programmed cell death 1 (PD-1) is an inhibitory immune checkpoint expressed on activatedT cells. Upon the formation of T cell receptor (TCR)-pMHC complexes, concomitant PD-1 ligation to its ligands programmed death-ligand 1 (PD-L1) or programmed death-ligand 2 (PD-L2) downregulates TCR s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shuang, Zhang, Min, Wu, Weiwei, Yuan, Zhijun, Tsun, Andy, Wu, Min, Chen, Bingliang, Li, Jia, Miao, Xiaoniu, Miao, Xiaoliang, Liu, Xiaolin, Yu, Dechao, Liu, Junjian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990132/ https://www.ncbi.nlm.nih.gov/pubmed/30406214 http://dx.doi.org/10.1093/abt/tby005

Ejemplares similares

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
por: Wang, Jie, et al.
Publicado: (2019)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020)

Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer
por: Lou, Beilei, et al.
Publicado: (2021)

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
por: Jiang, Haiping, et al.
Publicado: (2021)

The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China
por: Deng, Mi
Publicado: (2019)

Sintilimab: Pneumonitis: case report
Publicado: (2021)

Recent updates on Sintilimab in solid tumor immunotherapy
por: Liu, Xuhong, et al.
Publicado: (2020)

A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma
por: Zheng, Siming, et al.
Publicado: (2023)

Safety and clinical efficacy of sintilimab (anti-PD-1) in pediatric patients with advanced or recurrent malignancies in a phase I study
por: Que, Yi, et al.
Publicado: (2023)

Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review
por: Wang, Jian, et al.
Publicado: (2022)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review
por: Huang, Wenying, et al.
Publicado: (2023)

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report
por: Zhang, Lin, et al.
Publicado: (2020)

Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms
por: Jia, Ru, et al.
Publicado: (2022)

Sintilimab-induced erythema multiforme drug eruption in the treatment of sigmoid colon cancer: A case report and literature review
por: Zhang, Mei, et al.
Publicado: (2023)

Sintilimab-induced autoimmune diabetes: A case report and review of the literature
por: Yang, Jing, et al.
Publicado: (2022)

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

EDP-M plus sintilimab in the treatment of adrenocortical carcinoma: a case report
por: Zhang, Zhipeng, et al.
Publicado: (2022)

Sintilimab for the treatment of non-small cell lung cancer
por: Zhang, Lin, et al.
Publicado: (2022)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Radiation Recall Pneumonitis Induced by Sintilimab: A Case Report and Literature Review
por: Wang, Min, et al.
Publicado: (2022)

Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study
por: Tian, Zhichao, et al.
Publicado: (2022)

Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report
por: Li, Yi‐hui, et al.
Publicado: (2021)

Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China
por: Xu, Zhe, et al.
Publicado: (2023)

Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report
por: Lye, Ya-lei, et al.
Publicado: (2023)

A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy
por: Kuang, Zhihui, et al.
Publicado: (2020)

Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody
por: Wang, Yan, et al.
Publicado: (2020)

Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors
por: Huang, Nana, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
por: Ye, Zhuo-Miao, et al.
Publicado: (2022)

Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial
por: Guo, Chengxiang, et al.
Publicado: (2023)

Sintilimab: Aggravation of Coronavirus disease 2019: case report
Publicado: (2021)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

Sintilimab, a PD-1 Inhibitor, Completely Reversed Rarely Refractory Hypofibrinogenemia in a Gastric Cancer Patient: A Case Report and Review of the Literature
por: Ma, Shuzhen, et al.
Publicado: (2020)

Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature
por: Zhang, Yong, et al.
Publicado: (2021)

Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation
por: Wang, Mingzhu, et al.
Publicado: (2019)

Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
por: Zhang, Menglong, et al.
Publicado: (2022)

A rare presentation of Sintilimab-induced swelling along the vessels: Case report
por: Liu, Liqiong, et al.
Publicado: (2023)

Meta-analysis of the efficacy and safety of sintilimab for treating advanced non-small cell lung cancer
por: Xie, Jiejie, et al.
Publicado: (2022)

Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report
por: Zeng, Shu-Ying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_402oubnqdcapnv9fnokr28e5mq